COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid)

Claude Bernard University

Status: Completed

Conditions: Saliva; COVID19; Mouthwash

Treatments: Device: mouthrinse without bêta-cyclodextrin and citrox; Device: mouthrinse with bêta-cyclodextrin and citrox

Study type: Interventional

Funder types: Other

Identifiers

NCT04352959

BBCovid

Details and patient eligibility

About

Given the current lack of effective COVID-19 treatment, it is necessary to explore alternative methods to contain the spread of the infection, focusing in particular on its mode of transmission. The modes of person-to-person transmission of SARS-CoV-2 are direct transmission, such as sneezing, coughing, transmission through inhalation of small droplets, and transmission through contact, such as contact with nasal, oral and eye mucous membranes. SARS-CoV-2 can also be transmitted directly or indirectly through saliva. The use of antiviral mouthrinses may be used as adjunctive therapy.

Enrollment: 176 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of Covid-19 infection by the patient's general practitioner and hospital doctor
• Clinical signs started less than 8 days ago.
• Virological confirmation
• Understanding and acceptance of the trial.
• Written agreement to participate in the trial

Exclusion criteria

• Pregnancy
• Breastfeeding
• Inability to comply with protocol
• Lack of written agreement

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

176 participants in 2 patient groups, including a placebo group

mouth rinse with antiviral

Active Comparator group

Treatment:

Device: mouthrinse with bêta-cyclodextrin and citrox

mouth rinse without antiviral

Placebo Comparator group

Treatment:

Device: mouthrinse without bêta-cyclodextrin and citrox